Dinesh Patel

Person

Last mentioned: Mar 17, 2026

Timeline

  1. Data Readout

    Anticipated top-line data from the Phase 3 VERIFY clinical trial.

  2. Q4 Earnings

    Scheduled announcement of quarterly financial results and pipeline update.

  3. VERIFY Enrollment

    Completion of enrollment for the Phase 3 trial of rusfertide in polycythemia vera.

  4. J&J Milestone

    Protagonist receives $231M milestone payment for icotrokinra progress.

Stories mentioning Dinesh Patel 1

market-trends Neutral

Protagonist Therapeutics Eyes Pivotal Q4 Results Amid Oral Peptide Expansion

Protagonist Therapeutics (PTGX) is scheduled to release its quarterly earnings on Wednesday, March 18, 2026, with investors focused on the commercialization path for rusfertide and the Phase 3 progress of its oral IL-23 receptor antagonist, icotrokinra. The results will provide a critical update on the company's transition from a clinical-stage biotech to a potential commercial powerhouse in the immunology and hematology sectors.

2 sources